

## Research article

# Deciphering changes in the incidence of hemorrhagic stroke and cerebral venous sinus thrombosis during the coronavirus disease 2019 pandemic: a nationwide time-series correlation study

**Running title:** hemorrhagic stroke and CVST trends during COVID-19 pandemic

Soohyeon Cho,<sup>1,†</sup> Dong Kyu Kim,<sup>2,†</sup> Min Cheol Song,<sup>3</sup> Euiho Lee,<sup>4,5</sup> Seoncheol Park,<sup>6,7</sup> Darda Chung,<sup>10,\*</sup> Jongmok Ha<sup>8,9,\*</sup>

<sup>1</sup>Department of Nursing, Graduate School of Yonsei University, Seoul, Korea

<sup>2</sup>Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea

<sup>3</sup>Health Policy Division, Public Health Center, Yangpyeong County Office, Yangpyeong, Korea

<sup>4</sup>Department of Integrative Medicine, Yonsei University College of Medicine, Seoul, Korea

<sup>5</sup>Department of Internal Medicine, Yongin Severance Hospital, Yongin, Korea

<sup>6</sup>Department of Mathematics, Hanyang University, Seoul, Korea

<sup>7</sup>Research Institute for Natural Sciences, Hanyang University, Seoul, Korea

<sup>8</sup>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

<sup>9</sup>Neuroscience Center, Samsung Medical Center, Seoul, Korea

<sup>10</sup>Department of Neurology, Korea University Anam Hospital, Seoul, Korea

†These authors contributed equally to the study.

### \*Corresponding authors

**Corresponding author 1:** Jongmok Ha, MD

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine

81 Irwon-ro Gangnam-gu, Seoul, Republic of Korea (06351)

Tel: 82-2-3410-1426, Fax: 82-2-3410-3421

E-mail: [jongmok3245@gmail.com](mailto:jongmok3245@gmail.com)

**Corresponding author 2:** Darda Chung, MD

Department of Neurology, Korea University Anam Hospital

64, Goryeodae-ro 17ga-gil, Seongbuk-gu, Seoul, Republic of Korea

Tel: +82-10-3088-2370, Fax: +82-2-920-5893

E-mail: [vogmag0107@gmail.com](mailto:vogmag0107@gmail.com)

#### **ORCIDs**

Soohyeon Cho: 0000-0003-1904-3177

Dong Kyu Kim: 0000-0002-0742-6325

Min Cheol Song: 0000-0003-0117-614X

Euiho Lee: 0000-0002-1629-0976

Seoncheol Park: 0000-0002-8158-2617

Darda Chung: 0000-0002-5881-2672

Jongmok Ha: 0000-0003-4886-7650

## ABSTRACT

**Introduction:** Hemorrhagic stroke and cerebral venous sinus thrombosis (CVST) are associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination. We aimed to investigate changes in the incidence of hemorrhagic stroke and CVST in South Korea before and during the coronavirus disease 2019 pandemic and the factors associated with these changes.

**Materials and Methods:** We conducted a nationwide time-series study using population-based databases between 2007 and 2022. The real-world and forecasted incidences of acute non-traumatic subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), and CVST during the pandemic period (2020–2022) were estimated and compared with the pre-pandemic period (2007–2019). The prevalence of conventional risk factors was measured using time-series data. Finally, a time-series correlation analysis was performed to examine the temporal association between conventional risk factors, SARS-CoV-2 infection, and SARS-CoV-2 vaccination.

**Results:** The incidence of hemorrhagic stroke (SAH and ICH) was lower during the pandemic than during the pre-pandemic period. This observed decrease was associated with a reduction in the prevalence of conventional risk factors but not with SARS-CoV-2 infection or vaccination. The incidence of CVST was higher during the pandemic than during the pre-pandemic period, which may be temporally related to SARS-CoV-2 vaccination (Pearson correlation coefficient  $[r] = 0.349$ ,  $P = 0.031$ ).

**Conclusion:** We report reassuring evidence of hemorrhagic stroke associated with SARS-CoV-2 infection and vaccination. However, awareness of CVST may be required for future vaccine rollouts and SARS-CoV-2 outbreaks.

**Keywords:** hemorrhagic stroke; sinus thrombosis; SARS-CoV-2; COVID-19; time series

## 1. INTRODUCTION

Various neurological complications have been associated with SARS-CoV-2 infection and vaccination, raising public health concerns.<sup>1,2</sup> One of the controversial complications linked to these novel immune stimuli is hemorrhagic stroke and cerebral venous sinus thrombosis (CVST). These diseases are particularly relevant because they are major neurological conditions that can cause disabilities and societal burden.<sup>3</sup>

Hemorrhagic stroke or intracranial hemorrhage can crudely be dichotomized into intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH), each of which has overlapping causes (e.g., hypertension, usage of antithrombotic medication) and distinct etiologic risk factors (e.g., arteriovenous malformation for the former and intracranial aneurysm for the latter).<sup>4</sup> Moreover, CVST is a venous thrombotic disorder that can cause seizures and venous strokes in young adults and is often associated with the use of oral contraceptives or conditions that provoke serum hypercoagulability.<sup>5</sup>

Data-driven, self-controlled case series studies have identified an association between hemorrhagic stroke and SARS-CoV-2 vaccines. A study in England has reported an increased risk of ICH, 1–7 and 15–21 days after the first dose of BNT162b2 mRNA-based vaccine, and an increased risk of SAH following 0–14 days of SARS-CoV-2 infection.<sup>6</sup> Another study in Wales has reported an increased risk of hemorrhagic events at 8–14 days after the first dose of the BNT162b2 vaccine and 0–28 days after SARS-CoV-2 infection.<sup>7</sup> Furthermore, a Scottish study has identified increased hemorrhagic risks within 7–27 days of the first ChAdOx1-S/nCoV-19 vaccine dose and within 28 days of the first BNT162b2 vaccine dose.<sup>8</sup>

Viral vector-based SARS-CoV-2 vaccination, especially ChAdOx1-S/nCoV-19 was associated with CVST, which can be generally explained through mechanisms of thrombosis with thrombocytopenia syndrome (TTS).<sup>9–11</sup> A Scottish study has identified an increased risk of venous thromboembolism, 14–27 days and >28 days after the first dose of the ChAdOx1-S/nCoV-19 vaccine.<sup>8</sup> Another study in England has reported that the first dose of the ChAdOx1-S/nCoV-19 vaccine increased

the risk of CVST by an incidence risk ratio of 4.01 within 8–14 days.<sup>12</sup>

Although these studies provide sufficient evidence to suggest an association, none have validated these findings using a time-series study design, especially in the Korean population. Thus, this study aimed to investigate changes in the incidence of hemorrhagic stroke and CVST in South Korea before and during the coronavirus disease 2019 (COVID-19) pandemic. Furthermore, we explored the factors that could explain these changes.

## **2. MATERIALS AND METHODS**

### ***2.1. Study design and participants***

This nationwide time-series correlation study used population-based data from the Health Insurance Review and Assessment Service (HIRA), National Health Insurance Service (NHIS), and Korea Disease Control and Prevention Agency (KDCA) databases over a period of 15.5 years (January 2007 to July 2022).

Patients with non-traumatic SAH, ICH, and CVST were screened using the International Classification of Diseases (ICD)-10 codes I60, I61, and I67.6, respectively, based on the HIRA research data (M20230314001). To ascertain the acuteness of onset and urgency of the condition, we screened patients who had visited the emergency room because of hemorrhagic stroke or CVST. This decision assumed that acute conditions were more feasible in explaining the temporal association with a risk factor than subacute or chronic cases, which are inclined to have a mixed etiologic nature. Moreover, we excluded patients who had been diagnosed with hemorrhagic stroke or CVST within 2 years to avoid recurrence and those who had been diagnosed with acute ischemic stroke (ICD-10 code: I63) within 30 days to avoid the inclusion of hemorrhagic transformation cases. The crude incidence rate (CIR) for each month was calculated using the monthly incidence of the target disease as the numerator and the monthly average population as the denominator.<sup>13</sup>

## ***2.2 Data collection: patient-level data on risk factors***

We collected patient-level data on diagnoses, sociodemographic characteristics, comorbidities, and medication history using HIRA claims data. These included primary diagnoses, subdiagnoses, medical services received, medical institutions visited, and healthcare costs, including co-payments.

The relevant comorbid risk factors per incident cases were collected for hemorrhagic stroke on hypertension (HTN; I10–I15, I67.4, O10–11, and O13–16),<sup>14</sup> atrial fibrillation (AF; I48), end-stage renal disease (ESRD; N18.5), liver cirrhosis (LC; K70.30, K70.31, K71.7, K74.60, K74.69, and K76.6),<sup>15</sup> Marfan syndrome (Q87.4), autosomal dominant polycystic kidney disease (ADPKD; Q61.2), Moyamoya disease (MMD; I67.5), intracranial aneurysm (IA; I67.1 and Q28.3), and arteriovenous malformation (AVM; Q28.2).

For CVST, a history of cancer (C00–C97), head trauma within 3 months (S02.0, S02.8, S02.9, S06, and S07),<sup>16</sup> sepsis within 3 months (A40.0–A41.9, R65.1, and R57.2),<sup>17</sup> and pregnancy-related outcomes within 3 months (O80–O84) were recorded. We also attained relevant medication history in hemorrhagic stroke and CVST as follows: antiplatelet agents (AP; aspirin, dipyridamole, triflusal, clopidogrel, ticagrelor, ticlopidine, prasugrel, cilostazol, sarpogrelate, and beraprost) and oral anticoagulants (OAC; warfarin, rivaroxaban, apixaban, edoxaban, dabigatran, enoxaparin, dalteparin, and nadroparin) for hemorrhagic stroke and hormonal agents (bazedoxifene acetate, estrogen, and tibolone) and oral contraceptives (ethinyl estradiol, drospirenone, and levonorgestrel) for CVST. The prevalence of risk factors and medication use in incident hemorrhagic stroke or CVST cases was calculated on a monthly basis.

## ***2.3. Data collection: COVID-19 and vaccination data***

Nationwide SARS-CoV-2 infection data from January 2020 to December 2022 were collected as monthly outbreak summaries from the KDCA database. Data on SARS-CoV-2 vaccination status from February 2021 to December 2022 were extracted from the NHIS database.

For vaccination data, the vaccination rate was specified for the following three different platforms to allow an in-depth analysis of the biological mechanism: mRNA-based (including BNT162b2 and mRNA-1273), viral vector-based (including ChAdOx1 nCoV-19 and Ad26.COV2.S), and recombinant protein vaccines (NVX-CoV2373).

#### ***2.4. Statistical analysis***

In this study, total sex- and age-specific crude CIRs were calculated per 100,000 persons for the pre-pandemic (2007–2019) and pandemic (2020–2022) periods. The standardized morbidity ratio (SMR) was calculated as the ratio between the observed value during the pandemic and the pre-pandemic reference value.<sup>13,18</sup> The 95% confidence interval (CI) for SMR was estimated using Byar’s approximation method.<sup>19</sup>

Furthermore, the prevalence of comorbid risk factors and medication history were estimated in patients with hemorrhagic stroke and CVST. Prevalence data were compared between the pre-pandemic and pandemic periods. The traditional Wald method was used to examine the CI for the difference between proportions.<sup>20</sup> Finally, the weighted ranks of the risk factors were assessed considering the risk ratios collected from previous literature and used for crude comparisons between the pre-pandemic and pandemic periods.<sup>21-29</sup>

For the time-series analysis, a polynomial regression model for hemorrhagic stroke and a simple regression model for CVST were selected to forecast the expected incidence and 95% CIs during the pandemic (2021–2022) period based on the baseline pre-pandemic (2007–2019) incidence. The best-fit forecast models were compared based on the Akaike information criterion (AIC) and Bayesian information criterion (BIC). Models with the lowest AIC and BIC values were selected for the study.<sup>30</sup> The odds ratio (OR) between the expected (forecasted) value and the observed value (number of hemorrhagic stroke and CVST cases) was used for comparison. The OR, excluding 1.0, was clinically significant at the 5% level.

The temporal association between hemorrhagic stroke/CVST and prevalent comorbid risk factors, medication history, SARS-CoV-2 infection, and SARS-CoV-2 vaccination was determined using Pearson's correlation analysis of data collected during the pre-pandemic (2007–2019) and pandemic (2020–2022) periods. The degree of correlation followed a conventional paradigm (weak:  $0.10 \leq r < 0.30$ , moderate:  $0.30 \leq r < 0.50$ , and strong:  $r \geq 0.50$ ).<sup>31</sup>

### ***2.5. Standard protocol approval, registration, and patient consent***

The Institutional Review Board at Samsung Medical Center granted an exemption for review of this study because it involved the analysis of de-identified data already obtained through the epidemiological investigation, presented a minimal risk to the participants, and met the needs of current public health interests (identifier: SMC 2023-03-056). The need for consent was waived owing to the retrospective nature of this study, which used de-identified population data. All the experiments were conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology Reporting Guidelines.

## **3. RESULTS**

### ***3.1. Summary of collected data for analysis***

A total of 2,428,946 cases were collected for I60, and 5,906,398 cases were collected for I61. Among these, emergency cases were 156,783 cases for I60, 309,116 for I61, and 1,022 for I67.6. Altogether, 6,847 patients with stage I60 and 23,866 patients with stage I61 were excluded because they were diagnosed with stage I63 within 30 days. Moreover, 33,961, 34,323, and 75 cases of I60, I61, and I67.6, respectively, were excluded from the study owing to 2-year washout. Finally, 115,975 cases of I60, 250,927 cases of I61, and 947 cases of I67.6 were used for statistical analysis (Figure 1).



### 3.2. Incidence of hemorrhagic stroke (SAH and ICH) and CVST in pre-pandemic (2007–2019) versus pandemic (2020–2022) period

For SAH, the pre-pandemic CIR was 0.61 per 100,000 persons, whereas the pandemic CIR was slightly lower at 0.55 per 100,000 persons (SMR: 0.90; 95% CI, 0.89–0.91). The same downward trend in the incidence was observed in both sexes during the pandemic. When stratified by age, significantly lower CIR was observed for individuals aged  $\geq 30$  years during the pandemic period.

For ICH, the pre-pandemic CIR was 1.32 per 100,000 persons, whereas during the pandemic period, CIR decreased to 1.21 per 100,000 persons (SMR: 0.91; 95% CI, 0.91–0.92). A similar trend was observed for the sex-specific CIR in patients with ICH. Lower CIRs were observed in all age groups during the pandemic.

For CVST, the pre-pandemic CIR was 0.004 per 100,000 persons, whereas during the pandemic period, the CIR increased to 0.009 per 100,000 persons (SMR: 2.312; 95% CI, 2.018–2.650). The same trend was observed for the sex-specific CIR. When broken down into age groups, a higher CIR was observed in the 10–79-year age group (Table 1).

**Table 1. Sex-specific and age-specific crude cumulative incidence and rate ratio of hemorrhagic stroke and CVST during the pre-pandemic (2007 –2019) and pandemic (2020 – 2022) periods.** Statistically significant results were bold typed.

		2007-2019 (pre-pandemic)		2020-2022 (pandemic)		pre-pandemic vs pandemic
		N	CIR	N	CIR	SMR (95% CI)
Total		97,958	0.61	18,017	0.55	<b>0.9 (0.89–0.91)</b>
Sex						
I60	Male	39,484	0.50	6,680	0.41	<b>0.83 (0.81–0.85)</b>
	Female	58,474	0.73	11,337	0.68	<b>0.94 (0.92–0.96)</b>
Age						

	≤9	258	0.00	40	0.00	0.78 (0.56–1.08)
	10~19	623	0.07	92	0.06	0.87 (0.70–1.08)
	20~29	1,770	0.17	265	0.15	0.89 (0.78–1.01)
	30~39	6,396	0.56	784	0.38	<b>0.67 (0.62–0.72)</b>
	40~49	19,256	1.46	2,622	1.12	<b>0.77 (0.74–0.80)</b>
	50~59	25,644	1.96	4,410	1.64	<b>0.84 (0.81–0.87)</b>
	60~69	19,135	2.04	4,284	1.71	<b>0.84 (0.81–0.86)</b>
	70~79	16,164	2.79	3,007	1.98	<b>0.71 (0.68–0.74)</b>
	≥80	8,712	1.39	2,513	1.25	<b>0.91 (0.87–0.95)</b>
	<b>Total</b>	<b>211,386</b>	<b>1.32</b>	<b>39,541</b>	<b>1.21</b>	<b>0.91(0.91–0.92)</b>
	Sex					
	Male	114,902	1.45	21,403	1.33	<b>0.92(0.90–0.93)</b>
	Female	96,484	1.20	18,138	1.10	<b>0.91(0.90–0.93)</b>
	Age					
	≤9	1,396	0.02	111	0.01	<b>0.40(0.33–0.48)</b>
	10~19	1,946	0.23	225	0.16	<b>0.68(0.59–0.78)</b>
	20~29	3,386	0.33	466	0.27	<b>0.81(0.74–0.90)</b>
	30~39	8,950	0.79	1,291	0.62	<b>0.79(0.75–0.84)</b>
	40~49	27,076	2.05	3,709	1.59	<b>0.77(0.75–0.80)</b>
	50~59	46,006	3.51	7,424	2.77	<b>0.79(0.77–0.81)</b>
	60~69	43,208	4.62	8,803	3.51	<b>0.76(0.74–0.78)</b>
	70~79	47,448	8.20	8,488	5.59	<b>0.68(0.67–0.70)</b>
	≥80	31,970	5.09	9,024	4.51	<b>0.89(0.87–0.91)</b>
	<b>Total</b>	<b>643</b>	<b>0.004</b>	<b>304</b>	<b>0.009</b>	<b>2.31(2.02–2.65)</b>
	Sex					
	Male	340	0.004	169	0.010	<b>2.45(2.03–2.94)</b>
	Female	303	0.004	135	0.008	<b>2.17(1.77–2.65)</b>
	Age					
	≤9	12	0.000	2	0.000	0.83(0.22–3.24)
	10~19	23	0.003	12	0.008	<b>3.07(1.54–6.09)</b>
	20~29	93	0.009	54	0.031	<b>3.44(2.46–4.80)</b>
	30~39	124	0.011	44	0.021	<b>1.94(1.38–2.74)</b>
	40~49	125	0.009	51	0.022	<b>2.31(1.67–3.19)</b>

50~59	111	0.008	69	0.026	<b>3.03(2.25–4.09)</b>
60~69	82	0.009	41	0.016	<b>1.87(1.28–2.71)</b>
70~79	47	0.008	21	0.014	<b>1.70(1.02–2.84)</b>
≥80	26	0.004	10	0.005	1.21(0.59–2.47)

Crude CIR was calculated per 100 000 population.

‡The standardized morbidity ratio was calculated as (2020–2022 mean CIR)/(2007–2019 mean CIR).

Abbreviations: N, absolute number of patients; CIR, cumulative incidence rate; SMR, standardized morbidity ratio.

### ***3.3. Real-world incidence of hemorrhagic stroke and CVST during the pandemic (2007–2019) period versus forecasted estimate***

When spread by months, the observed incidence of SAH was significantly lower than the expected incidence in March, October, and December 2020; August and October–December 2021; January–April and July 2022 (rate ratios: 0.80–0.88). The observed incidence of ICH was within the expected incidence in all pandemic months except for March 2020 and March 2022 (rate ratios: 0.88 and 0.84, respectively). For CVST, the observed incidence was significantly higher than the forecasted incidence for May–July and October 2021, and June 2022 (rate ratios: 1.66–2.16) (Figure 2, Supplementary Material 2).

### ***3.4. Comparing the prevalence of conventional risk factors of hemorrhagic stroke and CVST during pre-pandemic (2007–2019) and pandemic (2020–2022) periods***

During the pandemic period, a significantly higher prevalence of AP or OAC therapy, HTN, ESRD, AF, LC, ADPKD, MMD, and IA was observed among incident patients with SAH than during the pre-pandemic period.

Moreover, a notably higher prevalence of AP or OAC therapy, HTN, ESRD, AF, LC, ADPKD, MMD, and IA was observed in patients with incident ICH during the pandemic period than during the

pre-pandemic period. Conversely, a notably lower prevalence of AVM was observed in patients with incident ICH during the pandemic compared with the pre-pandemic prevalence.

Finally, there was no significant difference between the prevalence of contraceptive and hormonal therapy, sepsis within 3 months, and cancer within one year in incident CVST cases (Figure 3, Supplementary Material 3).

### ***3.5. Time-series correlation analysis: hemorrhagic stroke/CVST incidence, comorbid risk factor prevalence, SARS-CoV-2, SARS-CoV-2 vaccination***

During the pre-pandemic period, prevalence of ESRD showed a mild negative temporal association ( $r = -0.151$ ,  $P = 0.039$ ) and intracranial aneurysm a mild positive temporal association ( $r = 0.222$ ,  $P = 0.005$ ) with SAH incidence. However, during the pandemic period, AP therapy and intracranial aneurysms showed a strong positive temporal association ( $r = 0.528$  and  $r = 0.650$ ;  $P = 0.007$  and  $P < 0.001$ , respectively) with the incidence of SAH. Additionally, a moderately positive temporal association was found between SAH incidence and the prevalence of HTN, AF, and MMD ( $r = 0.422$ ,  $0.368$ , and  $0.357$ ;  $P = 0.048$ ,  $0.021$ , and  $0.016$ , respectively) during the pandemic period.

During the pre-pandemic period, the prevalence of OAC therapy, ESRD, AF, LC, and MMD showed a mild-to-moderate negative association with ICH. However, the prevalence of AVM was moderately positively associated with the incidence of ICH ( $r = 0.305$ ,  $P < 0.001$ ). During the pandemic period, the prevalence of AP therapy and HTN demonstrated strong positive temporal associations with the incidence of ICH ( $r = 0.890$  and  $0.835$ , respectively;  $P < 0.001$  for both).

Finally, during the pre-pandemic period, the prevalence of contraceptive and hormonal therapies demonstrated a mildly positive temporal association with CVST incidence ( $r = 0.281$ ,  $P = 0.002$ ). During the pandemic period, this association was no longer significant, and CVST incidence demonstrated a moderately positive temporal association with COVID-19 vaccination ( $r = 0.349$ ,  $P = 0.031$ ) (Table 2).

**Table 2. Summary of time-series correlation analyses between hemorrhagic stroke & CVST and known risk factors during the pre-pandemic (2007 – 2019) and pandemic (2020 – 2022) periods.**  
Statistically significant results were bold typed.

		2007-2019		2020-2022	
		(pre-pandemic)		(pandemic)	
		r	p	r	p
I60	Antiplatelet therapy	-0.055	0.500	<b>0.528</b>	<b>0.007</b>
	Anticoagulant therapy	0.051	0.470	0.177	0.345
	Hypertension	-0.056	0.490	<b>0.422</b>	<b>0.048</b>
	End-stage renal disease	<b>-0.151</b>	<b>0.039</b>	-0.155	0.432
	Atrial fibrillation	0.022	0.760	<b>0.368</b>	<b>0.021</b>
	Liver cirrhosis	-0.127	0.094	0.115	0.543
	Marfan syndrome	0.061	0.432	0.064	0.394
	ADPKD	0.006	0.927	-0.024	0.900
	Moyamoya disease	0.071	0.408	<b>0.357</b>	<b>0.016</b>
	Intracranial aneurysm	<b>0.222</b>	<b>0.005</b>	<b>0.650</b>	<b>&lt;0.001</b>
	Arteriovenous malformation	0.028	0.711	0.131	0.523
	SARS-CoV-2 infection	-	-	-0.393	0.058
	SARS-CoV-2 vaccination	-	-	-0.279	0.093
	mRNA-based	-	-	-0.264	0.056
	Viral vector-based	-	-	-0.134	0.478
Recombinant protein	-	-	-0.359	0.095	
I61	Antiplatelet therapy	-0.192	0.054	<b>0.890</b>	<b>&lt;0.001</b>
	Anticoagulant therapy	<b>-0.240</b>	<b>0.009</b>	0.154	0.433
	Hypertension	-0.132	0.179	<b>0.835</b>	<b>&lt;0.001</b>
	End-stage renal disease	<b>-0.335</b>	<b>&lt;0.001</b>	0.176	0.346
	Atrial fibrillation	<b>-0.246</b>	<b>0.011</b>	0.438	0.052
	Liver cirrhosis	<b>-0.190</b>	<b>0.017</b>	0.389	0.089
	Marfan syndrome	0.015	0.867	0.252	0.170
	ADPKD	-0.102	0.119	0.137	0.567
	Moyamoya disease	<b>-0.177</b>	<b>0.028</b>	0.072	0.656
	Intracranial aneurysm	-0.030	0.703	0.233	0.146
Arteriovenous malformation	<b>0.305</b>	<b>&lt;0.001</b>	0.294	0.099	

	SARS-CoV-2 infection	-	-	-0.179	0.111
	SARS-CoV-2 vaccination	-	-	-0.185	0.321
	mRNA-based	-	-	-0.094	0.586
	Viral vector-based	-	-	-0.315	0.191
	Recombinant protein	-	-	-0.247	0.135
	Contraceptives and hormones $\leq$ 90d	0.281	<b>0.002</b>	0.047	0.699
	Sepsis within $\leq$ 90d	0.026	0.329	-	-
	Trauma within $\leq$ 90d	-	-	-	-
	Cancer within $\leq$ 1y	0.202	0.070	0.262	0.260
I676	SARS-CoV-2 infection	-	-	-0.311	0.256
	SARS-CoV-2 vaccination	-	-	0.349	<b>0.031</b>
	mRNA-based	-	-	0.289	0.061
	Viral vector-based	-	-	0.297	0.247
	Recombinant protein	-	-	-0.319	0.118

Note: Statistical significance was set at  $P < 0.05$ .

Abbreviations: r, Pearson's correlation coefficient; ADPKD, Autosomal Dominant Polycystic Kidney Disease.

#### 4. DISCUSSION

In this study we analyzed the incidences of new-onset hemorrhagic stroke and CVST before and after the COVID-19 pandemic. The observed incidence of hemorrhagic stroke was lower than expected during the pandemic period in certain months, and this trend was associated with a decrease in the diagnosis of conventional risk factors. The observed incidence of CVST was higher than expected during the pandemic period, and this trend may have been temporally associated with SARS-CoV-2 vaccination.

The incidence of SAH and ICH was lower during the pandemic period than during the pre-pandemic period. Owing to the affinity of SARS-CoV-2 to angiotensin-converting enzyme 2 prevalent in cerebrovascular endothelium,<sup>32</sup> the association between SARS-CoV-2 and acute ischemic stroke has

been implicated by several studies.<sup>33,34</sup> However, the association between SARS-CoV-2 and hemorrhagic stroke has been unclear.<sup>35,36</sup> Our result is in line with large population studies that have reported lower volume of hospitalization or incidence of SAH or ICH in patients during the pandemic.<sup>37,38</sup> This finding may be partly associated with hospital avoidance and saturation of emergency medical services during the height of the pandemic; specifically, during the peak delta variant outbreak in September 2021 and Omicron variant outbreak in January 2022 in South Korea. Additionally, this finding can be attributed to a decrease in the number of minor stroke cases, which do not exceed the healthcare-seeking behavior threshold.<sup>39,40</sup>

Despite large-scale reports on the potential causative association between hemorrhagic stroke and mRNA-based SARS-CoV-2 vaccines, our study did not reveal any temporal associations between the two. Furthermore, despite the increased mean prevalence of conventional risk factors in incident hemorrhagic stroke cases during the pandemic (i.e., higher dependability on these risk factors), the prevalence decreased during the pandemic, resulting in a positive temporal association with the declining incidence of hemorrhagic stroke. By contrast, no significant temporal association was observed between hemorrhagic stroke incidence and SARS-CoV-2 infection or vaccination, indicating that the decreased incidence of hemorrhagic stroke during the pandemic was more attributable to the downward trend in the prevalence of conventional risk factors than to SARS-CoV-2 infection or vaccination. Alternatively, the decreased incidence of hemorrhagic stroke during the pandemic may have contributed to the lower discovery rate of important conventional risk factors in incident cases. Nevertheless, the decreased prevalence of certain conventional risk factors (i.e., HTN, AP therapy, and AF) is not confined to incident hemorrhagic stroke cases and represents a larger nationwide trend, including the general population, supporting the initial hypothesis.<sup>41-43</sup>

When hemorrhagic stroke was categorized into SAH and ICH, the association between the prevalence of intracranial aneurysms and the decrease in SAH incidence increased from mild to strong during the pandemic, implying a stronger link. Several interpretations are possible. First, a notable

portion of patients who experience SAH are often diagnosed with the culprit aneurysm only at the time of stroke diagnosis. Hence, this finding may indicate a decrease in the number of undiagnosed aneurysmal SAH during the pandemic. Alternatively, this finding may be a result of decreased diagnosis of unruptured incidental intracranial aneurysms owing to lower access to healthcare during the pandemic, leading to low SAH awareness and suboptimal health-seeking behavior,<sup>44</sup> especially in conjunction with the prevalence trends of AP therapy, HTN, AF, and MMD, which all demonstrated a downward trend and a significant positive temporal association with SAH incidence. When analyzed by weighted ranks of attribution, no significant change in ranks in the conventional risk factor domain was recognized before and after the pandemic, implying a lack of intragroup alterations and a stable contribution of different mechanisms in patients with SAH. This indicates a quantitative game, not a qualitative game.

For CVST, we identified an association between vector-based vaccines and increased incidence, in agreement with previous studies that utilize different research designs.<sup>12</sup> Viral vector-based vaccines have reported to be associated with TTS-related CVST.<sup>9</sup> However, in our study, when divided into vaccine platforms, all three mechanisms (mRNA-based, viral vector-based, and protein recombinant) demonstrated a positive temporal association with CVST incidence, although no significant association was observed. Case reports of CVST following mRNA-based vaccines have been recognized,<sup>45,46</sup> implying the possibility of diverse biological mechanisms that may contribute to the development of CVST in vaccine recipients. Nevertheless, because of the limitations of our study, we believe that these findings should be interpreted with caution.

Our study has some limitations. First, observational time-series studies can only reveal possible temporal associations and not causation. Secondly, population-based data were not equally implicated for each individual, thus limiting the scope of interpretation. Third, we only included patients who visited the emergency medicine service, thereby limiting the number of patients evaluated in our study. However, acute-onset patients who may have a higher chance of being linked to the risk factors



evaluated in this study may need to be ascertained. Finally, our list of conventional risk factors was not exhaustive, and other factors may have influenced the change in hemorrhagic stroke or CVST incidence.

In conclusion, we offer insights into deciphering the changes in hemorrhagic stroke and CVST incidence over the years amidst the pandemic and its association with various conventional risk factors, SARS-CoV-2 infection, and SARS-CoV-2 vaccines. We believe that our study facilitates the public's understanding of a prevalent, notable cerebrovascular disease and provides reassuring evidence on the association between hemorrhagic stroke (SAH and ICH) and SARS-CoV-2 vaccines or infection, whereas reinforcing the already known association between SARS-CoV-2 vaccines and CVST for future vaccine rollout.

### **Acknowledgments**

The authors would like to acknowledge every frontline healthcare professional in the field who has strived to achieve the best patient outcomes during the tumultuous phase of the COVID-19 pandemic. We also thank Hyoseon Jeong for assistance with the pharmacological data search, which was crucial to our study.

### **Conflict of interest**

The authors report no relevant conflicts of interest.

### **Funding**

No funding was received for this study.

### **Financial disclosures**

The authors declare that there are no additional disclosures to report

### **Author contributions**

S.C. contributed to the acquisition and analysis of data and drafted a substantial portion of the manuscript, tables, and figures. D.K.K. contributed to the conception and design of the study and drafted a substantial portion of the manuscript. M.C.S. and E.L. contributed to the design of the study and interpretation of data. S.P. contributed to the acquisition, analysis, and interpretation of the data. J.W.C. contributed to the interpretation of the data and revision of the manuscript. D.C. and J.H. contributed to the conception and design of the study, interpretation of the data, and revision of the manuscript.

### **Data availability statement**

The datasets generated and/or analyzed in the current study are available from the corresponding author upon reasonable request.

## REFERENCES

1. Onk NGM, Ettema AR, van Berghem H, de Klerk JJ, van der Vegt JPM, van der Meulen M. SARS-CoV-2 vaccine-related neurological complications. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2022;43(4):2295-2297.
2. Sisniega DC, Reynolds AS. Severe Neurologic Complications of SARS-CoV-2. *Current treatment options in neurology*. 2021;23(5):14.
3. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Neurology*. 2021;20(10):795-820.
4. Shinohara Y. Hemorrhagic stroke syndromes: clinical manifestations of intracerebral and subarachnoid hemorrhage. *Handbook of clinical neurology*. 2009;93:577-594.
5. Ropper AH, Klein JP. Cerebral Venous Thrombosis. *The New England journal of medicine*. 2021;385(1):59-64.
6. Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. *Nat Med*. 2021;27(12):2144-2153.
7. Torabi F, Bedston S, Lowthian E, et al. Risk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test: a self-controlled case series analysis in Wales. *Scientific reports*. 2022;12(1):16406.
8. Simpson CR, Shi T, Vasileiou E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. *Nature medicine*. 2021;27(7):1290-1297.
9. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *The New England journal of medicine*. 2021;384(22):2092-2101.
10. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after

- ChAdOx1 nCoV-19 Vaccination. *The New England journal of medicine*. 2021;384(22):2124-2130.
11. Scully M, Singh D, Lown R, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. *The New England journal of medicine*. 2021;384(23):2202-2211.
  12. Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. *BMJ (Clinical research ed)*. 2021;374:n1931.
  13. Lee H, Heo N, Kwon D, Ha J. Deciphering changes in the incidence of the Guillain-Barré syndrome during the COVID-19 pandemic: a nationwide time-series correlation study. *BMJ neurology open*. 2022;4(2):e000378.
  14. Kim HC, Lee H, Lee HH, et al. Korea hypertension fact sheet 2021: analysis of nationwide population-based data with special focus on hypertension in women. *Clinical hypertension*. 2022;28(1):1.
  15. Dahiya M, Eboreime E, Hyde A, et al. International Classification of Diseases Codes are Useful in Identifying Cirrhosis in Administrative Databases. *Digestive diseases and sciences*. 2022;67(6):2107-2122.
  16. Saverino C, Swaine B, Jaglal S, et al. Rehospitalization After Traumatic Brain Injury: A Population-Based Study. *Archives of physical medicine and rehabilitation*. 2016;97(2 Suppl):S19-25.
  17. Fleischmann-Struzek C, Thomas-Rüddel DO, Schettler A, et al. Comparing the validity of different ICD coding abstraction strategies for sepsis case identification in German claims data. *PloS one*. 2018;13(7):e0198847.
  18. Lee H, Kwon D, Park S, Park SR, Chung D, Ha J. Temporal association between the age-specific incidence of Guillain-Barré syndrome and SARS-CoV-2 vaccination in Republic of Korea: a nationwide time-series correlation study. *Osong public health and research perspectives*. 2023;14(3):224-231.

19. Breslow NE, Day NE. Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. *IARC scientific publications*. 1987(82):1-406.
20. Agresti A, Caffo B. Simple and Effective Confidence Intervals for Proportions and Differences of Proportions Result from Adding Two Successes and Two Failures. *The American Statistician*. 2000;54(4):280-288.
21. Zeng Z, Chen J, Chen M, Ma F, Lv M, Zhang J. Risk factors for antiplatelet drug-associated intracranial hemorrhage: a systematic review and meta-analysis. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. 2022;43(12):6761-6769.
22. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. *Lancet (London, England)*. 1996;348(9025):423-428.
23. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne Risk Factor Study (MERFS) Group. *Stroke*. 1996;27(11):2020-2025.
24. Shiozawa M, Koga M, Inoue H, et al. Risk of both intracranial hemorrhage and ischemic stroke in elderly individuals with nonvalvular atrial fibrillation taking direct oral anticoagulants compared with warfarin: Analysis of the ANAFIE registry. *International journal of stroke : official journal of the International Stroke Society*. 2023;18(8):986-995.
25. Masson P, Kelly PJ, Craig JC, Lindley RI, Webster AC. Risk of Stroke in Patients with ESRD. *Clinical journal of the American Society of Nephrology : CJASN*. 2015;10(9):1585-1592.
26. Karhunen V, Bakker MK, Ruigrok YM, Gill D, Larsson SC. Modifiable Risk Factors for Intracranial Aneurysm and Aneurysmal Subarachnoid Hemorrhage: A Mendelian Randomization Study. *Journal of the American Heart Association*. 2021;10(22):e022277.
27. Amoozegar F, Ronksley PE, Sauve R, Menon BK. Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta-analysis. *Frontiers in neurology*.

- 2015;6:7.
28. Silvis SM, Hiltunen S, Lindgren E, et al. Cancer and risk of cerebral venous thrombosis: a case-control study. *Journal of thrombosis and haemostasis : JTH*. 2018;16(1):90-95.
  29. Cohoon KP, Ashrani AA, Crusan DJ, Petterson TM, Bailey KR, Heit JA. Is Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control Study. *The American journal of medicine*. 2018;131(3):307-316.e302.
  30. Vrieze SI. Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). *Psychological methods*. 2012;17(2):228-243.
  31. Parker RI, Hagan-Burke S. Useful effect size interpretations for single case research. *Behavior therapy*. 2007;38(1):95-105.
  32. Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *The Journal of pathology*. 2020;251(3):228-248.
  33. Yang Q, Tong X, George MG, Chang A, Merritt RK. COVID-19 and Risk of Acute Ischemic Stroke Among Medicare Beneficiaries Aged 65 Years or Older: Self-Controlled Case Series Study. *Neurology*. 2022;98(8):e778-e789.
  34. Tu TM, Seet CYH, Koh JS, et al. Acute Ischemic Stroke During the Convalescent Phase of Asymptomatic COVID-2019 Infection in Men. *JAMA network open*. 2021;4(4):e217498.
  35. Qureshi AI, Baskett WI, Huang W, et al. Intracerebral Hemorrhage and Coronavirus Disease 2019 in a Cohort of 282,718 Hospitalized Patients. *Neurocritical care*. 2022;36(1):259-265.
  36. Qureshi AI, Baskett WI, Huang W, et al. Subarachnoid Hemorrhage and COVID-19: An Analysis of 282,718 Patients. *World neurosurgery*. 2021;151:e615-e620.
  37. Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up. *J Neurol Neurosurg Psychiatry*. 2022.

38. Margos NP, Meintanopoulos AS, Filioglou D, Ellul J. Intracerebral hemorrhage in COVID-19: A narrative review. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*. 2021;89:271-278.
39. Quiles LEP, Diamante PAB, Pascual JLV. Impact of the COVID-19 Pandemic in the Acute Stroke Admissions and Outcomes in a Philippine Tertiary Hospital. *Cerebrovascular diseases extra*. 2022;12(2):76-84.
40. Gunnarsson K, Tofiq A, Mathew A, Cao Y, von Euler M, Ström JO. Changes in stroke and TIA admissions during the COVID-19 pandemic: A meta-analysis. *European stroke journal*. 2023:23969873231204127.
41. Lee M, Lee H, Park J, et al. Trends in hypertension prevalence, awareness, treatment, and control in South Korea, 1998-2021: a nationally representative serial study. *Scientific reports*. 2023;13(1):21724.
42. Wong PJ, Mosley SA, Ng TMH, Shooshtari A, Alexander GC, Qato DM. Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021). *American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists*. 2023;80(11):692-698.
43. Castanon A, Grasic K, Chen S, et al. The impact of the COVID-19 pandemic on cardiovascular disease prevention and corresponding geographical inequalities in England: interrupted time series analysis. *BMC public health*. 2023;23(1):2443.
44. Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association*. 2020;29(8):104949.
45. Qureshi MIA, Azam B, Waheed MA, Imran A. Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine. *BMJ case reports*. 2022;15(5).
46. Alhashim A, Hadhiah K, Al Khalifah Z, et al. Extensive Cerebral Venous Sinus Thrombosis

(CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman. *The American journal of case reports*. 2022;23:e934744.



## FIGURE LEGENDS

**Figure 1. Flow diagram of study participants.** HIRA, Health Insurance Review & Assessment Service.

**Figure 2. Real-world incidence of hemorrhagic stroke and cerebral venous sinus thrombosis from 2020 to 2022 versus estimated incidence projections based on 2007–2019 incidence data.** The blue lines denote the observed incidence, green line the expected incidence, darker and lighter grey shades 80% and 95% CI of the predicted incidence, respectively. (a) I60. (b) I61. (c) I67.6.

**Figure 3. Visualization of known risk factors for the prevalence of hemorrhagic stroke and cerebral venous sinus thrombosis (CVST) from the pre-pandemic (2007–2019) versus post-pandemic (2020–2022) period through a pyramid chart.** Blue bars in the left indicate pre-pandemic prevalence of incident hemorrhagic stroke or CVST cases. Red bars in the right indicate pandemic prevalence of incident hemorrhagic stroke or CVST cases. The x-axis denotes prevalence metrics per 100,000 persons. (a) I60, (b) I61, and (c) I67.6.

Abbreviations: HTN, hypertension; ESRD, end-stage renal disease; Afib, atrial fibrillation; LC, liver cirrhosis; ADPKD, autosomal dominant polycystic kidney disease; MMD, Moyamoya disease; AVM, arteriovenous malformation.

medRxiv preprint doi: <https://doi.org/10.1101/2024.03.17.24304431>; this version posted March 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).




Figure 1





Figure 2



medRxiv preprint doi: <https://doi.org/10.1101/2024.03.17.24304431>; this version posted March 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).





Figure 3